POLIVY plus a chemotherapy regimen of bendamustine and a rituximab product (POLIVY+BR) was compared with BR by itself in a clinical trial.
Patients received either POLIVY+BR or BR by itself every 21 days for 6 treatment cycles. Both patients and healthcare providers knew which treatment had been given.
In order to see how POLIVY works, patients in the study were also sorted by the length of time they responded to a previous treatment (also known as duration of response, or DoR).
HSCT=hematopoietic stem cell transplantation.
*Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which cancer cells from other parts of the body form in the brain and/or spinal cord.
†Transformed lymphoma occurs when a slow-growing lymphoma develops into a more aggressive one.
Please talk to your doctor about whether POLIVY is right for you
See the efficacy results of POLIVY+BR
Learn about how POLIVY was designed to treat R/R DLBCL
See the infusion process and dosing schedule for POLIVY+BR
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.